Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, Francesco Paolo Tambaro, MD, PhD, Nebiyou Bekele, Hui Yang, Farhad Ravandi, MD, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Marina Konopleva, M.D., Ph.D., Stefan Faderl, MD, Jorge E. Cortes, Mark Brandt, BS, Yumin Hu, PhD, Deborah McCue, Willie Mae Newsome, RN, Sherry Pierce, RN, BS, Marcos DeLima, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 763.

https://doi.org/10.1182/blood.V118.21.763.763

Published: 2011

Journal Articles

Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, MD, Francesco Paolo Tambaro, MD, PhD, Nebiyou Bekele, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Marina Konopleva, MD, PhD, Tapan Kadia, MD, Jorge E. Cortes, Hui Yang, Mark Brandt, BS, Sherry A. Pierce, RN, BS, Willie Mae Newsome, RN, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2189.

https://doi.org/10.1182/blood.V116.21.2189.2189

Published: 2010

Journal Articles

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Deborah McCue, PhDP, B. Nebiyou Bekele, PhD, Lianchun Xiao, Gautam Borthakur, MD, Hagop Kantarjian, MD

Blood (2009) 114 (22): 993.

https://doi.org/10.1182/blood.V114.22.993.993

Published: 2009

Journal Articles

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

Guillermo Garcia-Manero, MD, Francesco Paolo Tambaro, MD, PhD, B. Nebiyou Bekele, PhD, Elias Jabbour, MD, Farhad Ravandi, M.D., Hui Yang, MD, PhD, Gautam Borthakur, MD, Tapan Kadia, MD, Jorge Cortes, MD, Stefan Faderl, MD, Marina Konopleva, MD, PhD, Sherry Pierce, RN, Jan A. Burger, MD, PhD, Zeev Estrov, MD, Susan O'Brien, M.D., Deborah Thomas, Willie Newsome, RN, Hagop Kantarjian, MD

Blood (2009) 114 (22): 1055.

https://doi.org/10.1182/blood.V114.22.1055.1055

Published: 2009

Journal Articles

Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study

Ayalew Tefferi, MD, Srdan Verstovsek, Giani Barosi, Francesco Passamonti, MD, Gail J. Roboz, MD, Heinz Gisslinger, Ronald Paquette, MD, Francisco Cervantes, MD, Candido E. Rivera, MD, H. Joachim Deeg, Juergen Thiele, Hans Michael Kvasnicka, James W. Vardiman, MD, B. Nebiyou Bekele, PhD, Ruben A. Mesa, MD, FACP, Robert P Gale, Hagop M Kantarjian

Blood (2008) 112 (11): 663.

https://doi.org/10.1182/blood.V112.11.663.663

Published: 2008

Journal Articles

Bone Loss in Patients with Previously Untreated Lymphoma: The Effect of Periodontal Disease on the Use of Zoledronic Acid

Vince D. Cataldo, M.D., Michael A. Thompson, M.D., PhD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, B. Nebiyou Bekele, PhD, Camilo Jimenez, M.D., William A. Murphy, M.D., Auris O. Huen, Pharm.D., Rebecca B. Arbuckle, Pharm.D., Michelle A. Fanale, M.D., Luis E. Fayad, M.D., Nathan Fowler, M.D., Larry W. Kwak, M.D., Peter W. McLaughlin, M.D., Sattva S. Neelapu, M.D., Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, M.D., Fredrick B. Hagemeister, M.D.

Blood (2008) 112 (11): 5297.

https://doi.org/10.1182/blood.V112.11.5297.5297

Published: 2008

Journal Articles

An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC).

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Jennifer Cassat, Deborah Blamble, PHDP, B. Nebiyou Bekele, PhD, Miloslav Beran, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Jan Burger, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 2840.

https://doi.org/10.1182/blood.V110.11.2840.2840

Published: 2007

Journal Articles

Cyclin D1 Polymorphisms as Predictive and Prognostic Molecular Markers in 90 Mantle Cell Lymphoma Patients Treated with R-HyperCVAD.

Michael A. Thompson, MD, PhD, Tapan M. Kadia, MD, B. Nebiyou Bekele, PhD, Michael Wang, MD, Jorge E. Romaguera, MD

Blood (2007) 110 (11): 1581.

https://doi.org/10.1182/blood.V110.11.1581.1581

Published: 2007

Journal Articles

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia

Charles Koller, B. Nebiyou Bekele, Xian Zhou, Charles Park, Zeev Estrov, Susan O'Brien, Michael Keating, Iman Jilani, Francis J. Giles, Hagop M. Kantarjian, Maher Albitar

Blood (2006) 108 (3): 1001–1006.

https://doi.org/10.1182/blood-2005-05-2110

Published: 2006

Journal Articles

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center

Blood (2006) 107 (3): 880–884.

https://doi.org/10.1182/blood-2005-06-2450

Published: 2006

Journal Articles

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

Alfonso Quintas-Cardama, Hagop Kantarjian, Moshe Talpaz, Susan O'Brien, Guillermo Garcia-Manero, Srdan Verstovsek, Mary Beth Rios, Kimberly Hayes, Armand Glassman, B. Nebiyou Bekele, Xian Zhou, Jorge Cortes

Blood (2005) 105 (6): 2281–2286.

https://doi.org/10.1182/blood-2004-06-2208

Published: 2005

Journal Articles

Matched Pairs Analysis of IV vs. PO Busulfan as a Conditioning Agent Prior to Transplantation.

Kathleen A. Sobocinski, MS, Peter F. Thall, PhD, B. Nebiyou Bekele, PhD, John P. Klein, PhD, Shari Lennon, Mary M. Horowitz, MS, MD, Borje Andersson, MD, PhD

Blood (2004) 104 (11): 349.

https://doi.org/10.1182/blood.V104.11.349.349

Published: 2004

Journal Articles

Intracranial Hemorrhage (ICH) in Patients (pts) with Newly Diagnosed Leukemia: Incidence and Effect on Outcome.

Yasuhiro Oki, M.D., Elias Jabbour, M.D., Hagop Kantarjian, M.D., Elihu Estey, M.D., Jorge E. Cortes, M.D., Stefan Faderl, M.D., Sherry Pierce, RN, BSN, BA, Xian Zhou, MS, BS, B. Nebiyou Bekele, Ph.D., Guillermo Garcia-Manero, M.D.

Blood (2004) 104 (11): 4530.

https://doi.org/10.1182/blood.V104.11.4530.4530

Published: 2004

Journal Articles

Thrombopoietin as an Independent Prognostic Marker in Chronic Lymphocytic Leukemia.

Charles Asa Koller, MD, B. Nebiyou Bekele, PhD, Xian Zhou, PhD, Charles Park, BS, Zeef Estrove, MD, Susan O’Brien, MD, Michael Keating, MD, Iman Jilani, PhD, Francis J. Giles, MD, Hagop M. Kantarjian, MD, Maher Albitar, MD

Blood (2004) 104 (11): 1905.

https://doi.org/10.1182/blood.V104.11.1905.1905

Published: 2004

NARROW

Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study

Bone Loss in Patients with Previously Untreated Lymphoma: The Effect of Periodontal Disease on the Use of Zoledronic Acid

An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC).

Cyclin D1 Polymorphisms as Predictive and Prognostic Molecular Markers in 90 Mantle Cell Lymphoma Patients Treated with R-HyperCVAD.

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

Matched Pairs Analysis of IV vs. PO Busulfan as a Conditioning Agent Prior to Transplantation.

Intracranial Hemorrhage (ICH) in Patients (pts) with Newly Diagnosed Leukemia: Incidence and Effect on Outcome.

Thrombopoietin as an Independent Prognostic Marker in Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only